| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9164593 | Chest | 2005 | 7 Pages |
Abstract
We conclude that mortality is the most inclusive end point for future trials of IFN- γ1b in patients with IPF, and that a > 10% decrement in the percentage of predicted FVC represents a valid measure of disease progression.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
King MD, FCCP, Safrin MD, Starko Karen M., Brown MD, FCCP, Noble Paul W., Raghu MD, FCCP, Schwartz MD, FCCP,